


We claim:

1. (currently amended) A compound of the formula I,



I

wherein

$\text{R}_1$  and  $\text{R}_2$  are each independently H, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or (C<sub>1</sub>-C<sub>6</sub>)-alkyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl is optionally substituted by OH, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>4</sub>)-alkyl or N[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>;

$\text{R}_3$  and  $\text{R}_4$  are each independently F, Cl, Br, OH, NO<sub>2</sub>, CN, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl or (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl and (C<sub>2</sub>-C<sub>6</sub>)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;

$\text{R}_5$  is H, F, Cl, Br, OH, NO<sub>2</sub>, CN, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl or (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl and (C<sub>2</sub>-C<sub>6</sub>)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;

$\text{A}$  is H, F, Cl, Br, OH, NO<sub>2</sub>, CN, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, S(O)<sub>1-2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl-, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub> or NHCOR<sub>6</sub>, wherein

said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, S(O)<sub>1-2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl-, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, SO<sub>2</sub>NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl and SO<sub>2</sub>N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub> are optionally mono- or polysubstituted by F, Cl, Br, ~~COOH~~, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub> or OCO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl;

R6 is H, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl-(C<sub>1</sub>-C<sub>4</sub>)-alkylene, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-CONH<sub>2</sub>, (C<sub>6</sub>-C<sub>10</sub>)-aryl, (C<sub>1</sub>-C<sub>4</sub>)-alkylene-(C<sub>6</sub>-C<sub>10</sub>)-aryl, heteroaryl, (C<sub>1</sub>-C<sub>4</sub>)-alkylene-heteroaryl or CO-heteroaryl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl-(C<sub>1</sub>-C<sub>4</sub>)-alkylene, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH and (C<sub>1</sub>-C<sub>6</sub>)-alkylene-CONH<sub>2</sub> are optionally mono- or polysubstituted by F, Cl, Br, O(C<sub>1</sub>-C<sub>4</sub>-alkyl), COO-(C<sub>1</sub>-C<sub>4</sub>-alkyl) or N-[(C<sub>1</sub>-C<sub>4</sub>)-alkyl]<sub>2</sub> and said (C<sub>6</sub>-C<sub>10</sub>)-aryl, (C<sub>1</sub>-C<sub>4</sub>)-alkylene-(C<sub>6</sub>-C<sub>10</sub>)-aryl, heteroaryl, (C<sub>1</sub>-C<sub>4</sub>)-alkylene-heteroaryl and CO-heteroaryl are optionally mono- or polysubstituted by F, Cl, Br, NO<sub>2</sub>, CN, O-(C<sub>1</sub>-C<sub>4</sub>-alkyl), S-COO(C<sub>1</sub>-C<sub>4</sub>-alkyl), COO-(C<sub>1</sub>-C<sub>4</sub>-alkyl), N-[(C<sub>1</sub>-C<sub>4</sub>)-alkyl]<sub>2</sub> or (C<sub>1</sub>-C<sub>6</sub>)-alkyl;

n is 0, 1, 2 or 3;

m is 1, 2, 3, 4 or 5;

o is 0, 1, 2 or 3;

Het is a heterocyclic 4- to 7-membered ring which may contain up to four N, O or S heteroatoms and wherein said heterocyclic 4- to 7-membered ring is optionally substituted by R7, R8 and R9, with the proviso that said heterocyclic 4- to 7-membered ring cannot be pyrrole; and

R7, R8, and R9 are each independently H, F, Cl, Br, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, OH, oxo, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, NH<sub>2</sub>, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, COOH, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-aryl or (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-

C<sub>6</sub>)-alkyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-aryl and (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl are optionally substituted by COOH, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, OCO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, F, Cl, (C<sub>1</sub>-C<sub>6</sub>)-alkyl or O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl;

and two radicals selected from said R7, R8 and R9 may optionally be bonded together to form a ring fused onto said heterocyclic 4- to 7-membered ring;

and pharmaceutically acceptable salts thereof.

2. (currently amended) The compound of Claim 1 wherein

R1 and R2 are H;

R3 and R4 are each independently F, Cl or Br;

R5 is H, F, Cl, Br, OH, NO<sub>2</sub>, CN, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl or (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl and (C<sub>2</sub>-C<sub>6</sub>)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;

A is H, F, Cl, Br, OH, NO<sub>2</sub>, CN, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, S(O)<sub>1,2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl-, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, ~~COOH~~, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub> or NHCOR<sub>6</sub>, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, S(O)<sub>1,2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl-, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, SO<sub>2</sub>NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl and SO<sub>2</sub>N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub> are optionally mono- or polysubstituted by F, Cl, Br, ~~COOH~~, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub> or OCO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl;


R6 is H, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl-(C<sub>1</sub>-C<sub>4</sub>)-alkylene, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-CONH<sub>2</sub>, (C<sub>6</sub>-C<sub>10</sub>)-aryl, (C<sub>1</sub>-C<sub>4</sub>)-alkylene-(C<sub>6</sub>-C<sub>10</sub>)-aryl, heteroaryl, (C<sub>1</sub>-C<sub>4</sub>)-alkylene-heteroaryl or CO-heteroaryl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl-(C<sub>1</sub>-C<sub>4</sub>)-alkylene, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH and (C<sub>1</sub>-C<sub>6</sub>)-alkylene-CONH<sub>2</sub> are optionally mono- or polysubstituted by F, Cl, Br, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, or N-[(C<sub>1</sub>-C<sub>4</sub>)-alkyl]<sub>2</sub>, and said (C<sub>6</sub>-C<sub>10</sub>)-aryl, (C<sub>1</sub>-C<sub>4</sub>)-alkylene-(C<sub>6</sub>-C<sub>10</sub>)-aryl, heteroaryl, (C<sub>1</sub>-C<sub>4</sub>)-alkylene-heteroaryl and CO-heteroaryl are optionally mono- or polysubstituted by F, Cl, Br, NO<sub>2</sub>, CN, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, S-COO(C<sub>1</sub>-C<sub>4</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>4</sub>)-alkyl]<sub>2</sub> or (C<sub>1</sub>-C<sub>6</sub>)-alkyl;

n is 0, 1 or 2;

m is 1;

o is 0 or 1;

Het is a heterocyclic 4- to 7-membered ring selected from triazolyl, tetrazolyl, oxadiazolyl,

pyrazolyl, benzimidazolyl, furyl, triazinyl or  wherein said heterocyclic 4- to 7-membered ring is optionally substituted by R7, R8 and R9; and

R7, R8, and R9 are each independently H, F, Cl, Br, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, OH, oxo, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, NH<sub>2</sub>, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, COOH, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-aryl or (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-aryl and (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl are optionally substituted by COOH, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, OCO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, F, Cl, (C<sub>1</sub>-C<sub>6</sub>)-alkyl or O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl;

and two radicals selected from said R7, R8 and R9 may optionally be bonded together to form a ring fused onto said heterocyclic 4- to 7-membered ring;

and pharmaceutically acceptable salts thereof.

3. (original) The compound of Claim 2 wherein

R1 and R2 are H;

R3 and R4 are each independently F, Cl or Br;

R5 is H, F, Cl, Br, OH, NO<sub>2</sub>, CN, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl or (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl and (C<sub>2</sub>-C<sub>6</sub>)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;


A is H, F, Cl, Br, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, CF<sub>3</sub>, OCF<sub>3</sub>, NO<sub>2</sub>, CN, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl;

n is 0, 1 or 2;

m is 1;

o is 0 or 1;

Het is a heterocyclic 4- to 7-membered ring group selected from triazolyl, tetrazolyl,


oxadiazolyl, furyl, triazinyl or , wherein said 4- to 7-membered heterocyclic ring is optionally substituted by R7, R8 and R9; and

R7, R8, and R9 are each independently H, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, OH, oxo, NH<sub>2</sub>, COOH, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl,

COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl and CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub> are optionally substituted by COOH;

and pharmaceutically acceptable salts thereof.

4. (original) The compound of Claim 1 wherein the compound has the structure Ia



Ia

wherein

R5 is H, F, Cl, Br, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, CF<sub>3</sub>, OCF<sub>3</sub>, NO<sub>2</sub>, CN, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl;

A is H, F, Cl, Br, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, CF<sub>3</sub>, OCF<sub>3</sub>, NO<sub>2</sub>, CN, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl;

R7 is H, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-aryl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl or O-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-aryl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl and O-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;

R8 is -(C=O)-X;


X is OH, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, NH<sub>2</sub>, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or N-((C<sub>1</sub>-C<sub>6</sub>)-alkyl)<sub>2</sub>;

m is 1 or 2; and

n is 1 or 2;

and pharmaceutically acceptable salts thereof.

5. (currently amended) The compound of Claim 1 wherein the compound has the structure Iaa



Iaa

wherein

R5 is H or F;

A is H, F, Cl, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, CF<sub>3</sub>, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, C≡OH or SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl;

R7 is H or phenyl;

R8 is -(C=O)-X; and

X is OH, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, NH<sub>2</sub>, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>;

and pharmaceutically acceptable salts thereof.


6. (original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of Claim 1.

7. (currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of Claim 1 and at least one further active ingredient.

8. (original) The pharmaceutical composition of Claim 7, wherein said further active ingredient is selected from the group consisting of:  
antidiabetics, hypoglycemic active ingredients, HMG-CoA reductase inhibitors, cholesterol absorption inhibitors, PPAR gamma agonists, PPAR alpha agonists, PPAR alpha/gamma agonists, fibrates, MTP inhibitors, bile acid absorption inhibitors, CETP inhibitors, polymeric bile acid adsorbents, LDL receptor inducers, ACAT inhibitors, antioxidants, lipoprotein lipase inhibitors, ATP-citrate-lyase inhibitors, squalene synthetase inhibitors, lipoprotein(a) antagonists, lipase inhibitors, insulins, sulfonylureas, biguanides, meglitinides, thiazolidinediones,  $\alpha$ -glucosidase inhibitors, active ingredients acting on the ATP-dependent potassium channel of the beta cells, CART agonists, NPY agonists, MC4 agonists, orexin agonists, H3 agonists, TNF agonists, CRF agonists, CRF BP antagonists, urocortin agonists,  $\beta$ 3 agonists, MSH (melanocyte-stimulating hormone) agonists, CCK agonists, serotonin reuptake inhibitors, mixed serotonergic and noradrenergic compounds, 5HT agonists, bombesin agonists, galanin antagonists, growth hormones, growth hormone-releasing compounds, TRH agonists, uncoupling protein 2 or 3 modulators, leptin agonists, DA agonists (bromocriptine, Doprexin), lipase/amylase inhibitors, PPAR modulators, RXR modulators or TR- $\beta$  agonists or amphetamines.
9. (original) A method of reducing blood sugar comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.
10. (original) A method for treating lipid and carbohydrate metabolism disorders comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.
11. (original) A method for treating type 2 diabetes comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.
12. (original) A method for treating arteriosclerotic symptoms comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.
13. (original) A method for treating insulin resistance comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.



14. (currently amended) A process for preparing a compound of Claim 1, which comprises reacting a urea of formula 2 with a compound of formula 4



wherein

**R1 and R2** are each independently H, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or (C<sub>1</sub>-C<sub>6</sub>)-alkyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl is optionally substituted by OH, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>4</sub>)-alkyl or N[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>;

**R3 and R4** are each independently F, Cl, Br, OH, NO<sub>2</sub>, CN, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl or (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl and (C<sub>2</sub>-C<sub>6</sub>)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;

**R5** is H, F, Cl, Br, OH, NO<sub>2</sub>, CN, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl or (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl and (C<sub>2</sub>-C<sub>6</sub>)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;


**A** is H, F, Cl, Br, OH, NO<sub>2</sub>, CN, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, S(O)<sub>1,2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl-, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, COOH, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub> or NHCOR<sub>6</sub>, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, S(O)<sub>1,2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl-, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, COO-(C<sub>1</sub>-C<sub>6</sub>)-

alkyl, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, SO<sub>2</sub>NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl and SO<sub>2</sub>N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub> are optionally mono- or polysubstituted by F, Cl, Br, ~~COOH~~, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub> or OCO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl;



n is 0, 1, 2 or 3;

R7 and R8 are each independently H, F, Cl, Br, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, OH, oxo, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, NH<sub>2</sub>, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, COOH, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-aryl or (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-aryl and (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl are optionally substituted by COOH, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, OCO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, F, Cl, (C<sub>1</sub>-C<sub>6</sub>)-alkyl or O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl; and said R7 and R8 may optionally be bonded together to form a ring fused onto said heterocyclic 4- to 7-membered ring; and

Y is Cl or



15. (currently amended) A process for preparing a compound of Claim 1, which comprises reacting an aniline derivative of formula 3 with a compound of formula 4



wherein

- R2 is H, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or (C<sub>1</sub>-C<sub>6</sub>)-alkyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl is optionally substituted by OH, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>4</sub>)-alkyl or N[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>;
- R3 and R4 are each independently F, Cl, Br, OH, NO<sub>2</sub>, CN, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl or (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl and (C<sub>2</sub>-C<sub>6</sub>)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;
- R5 is H, F, Cl, Br, OH, NO<sub>2</sub>, CN, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl or (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl and (C<sub>2</sub>-C<sub>6</sub>)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;
- A is H, F, Cl, Br, OH, NO<sub>2</sub>, CN, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, S(O)<sub>1-2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl-, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, ~~COOH~~, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub> or NHCOR<sub>6</sub>, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, S(O)<sub>1-2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl-, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, SO<sub>2</sub>NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl and SO<sub>2</sub>N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub> are optionally mono- or polysubstituted by F, Cl, Br, ~~COOH~~, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub> or OCO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl;
- n is 0, 1, 2 or 3;
- R7 and R8 are each independently H, F, Cl, Br, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, OH, oxo, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, NH<sub>2</sub>, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, COOH, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-aryl or (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-

C<sub>6</sub>)-alkyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-aryl and (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl are optionally substituted by COOH, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, OCO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, F, Cl, (C<sub>1</sub>-C<sub>6</sub>)-alkyl or O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl;

and said R<sub>7</sub> and R<sub>8</sub> may optionally be bonded together to form a ring fused onto said heterocyclic 4- to 7-membered ring; and

Y

is -N=C=O.